Europe
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
Michael Yu, chairman and chief executive officer of Innovent Biologics, said the deal with Roche will help the company continue to move forward in the cellular therapy space.
Researchers with The U.S. Oncology Network discovered AstraZeneca’s Calquence (acalabrutinib) benefited a small number of patients who have severe infections of the novel coronavirus.
The results of Lumasiran were presented at the European Renal Association-European Dialysis and Transplant Association International Congress.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
Shares of Gilead Sciences jumped in pre-market trading this weekend following reports that the company has been approached by U.K. pharma giant AstraZeneca regarding a potential merger.
The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
PRESS RELEASES